Globus Medical (GMED) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Globus Medical (GMED) PT Raised to $65 at Needham & Company
August 2, 2018 8:15 AM EDTNeedham & Company raised its price target on Globus Medical (NYSE: GMED) to $65.00 (from $58.00) while maintaining a Buy rating following 2Q earnings report. Revenue was $173M vs. consensus of $168M and non-GAAP EPS was $0.44 vs. consensus of $0.35.
For 2018, GMED raised its revenue... More
